Salicylate, diflunisal and their metabolites inhibit CBP/p300 and exhibit anticancer activity
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Salicylate and acetylsalicylic acid are potent and widely used anti-inflammatory drugs. They are thought to exert their therapeutic effects through multiple mechanisms, including the inhibition of cyclo-oxygenases, modulation of NF-κB activity, and direct activation of AMPK. However, the full spectrum of their activities is incompletely understood. Here we show that salicylate specifically inhibits CBP and p300 lysine acetyltransferase activity in vitro by direct competition with acetyl-Coenzyme A at the catalytic site. We used a chemical structure-similarity search to identify another anti-inflammatory drug, diflunisal, that inhibits p300 more potently than salicylate. At concentrations attainable in human plasma after oral administration, both salicylate and diflunisal blocked the acetylation of lysine residues on histone and non-histone proteins in cells. Finally, we found that diflunisal suppressed the growth of p300-dependent leukemia cell lines expressing AML1-ETO fusion protein in vitro and in vivo . These results highlight a novel epigenetic regulatory mechanism of action for salicylate and derivative drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892
Type 2 diabetes as an inflammatory disease
Donath, M. Y., & Shoelson, S. E. (2011) · Nature Reviews Immunology · doi:10.1038/nri2925 · Cited by 3,737
Mitchell, J. A., Akarasereenont, P., Thiemermann, C., Flower, R. J., & Vane, J. R. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11693 · Cited by 1,659
Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF‐κB
Chen, L., Mu, Y., & Greene, W. C. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf660 · Cited by 827
Regulation of activity of the transcription factor GATA-1 by acetylation
Boyes, J., Byfield, P., Nakatani, Y., & Ogryzko, V. (1998) · Nature · doi:10.1038/25166 · Cited by 694 · cited 1×
“pCi-p300 and pCi-PCAF are described elsewhere (Boyes et al., 1998).”
Regulation of the p300 HAT domain via a novel activation loop
Thompson, P. R., Wang, D., Wang, L., Fulco, M., Pediconi, N., Zhang, D., An, W., Ge, Q., Roeder, R. G., Wong, J., et al. (2004) · Nature Structural & Molecular Biology · doi:10.1038/nsmb740 · Cited by 423
Self-citationThe Leukemogenicity of AML1-ETO Is Dependent on Site-Specific Lysine Acetylation
Wang, L., Gural, A., Sun, X.-J., Zhao, X., Perna, F., Huang, G., Hatlen, M. A., Vu, L., Liu, F., Xu, H., et al. (2011) · Science · doi:10.1126/science.1201662 · Cited by 242
Self-citationZhang, Y., Qiu, J., Wang, X., Zhang, Y., & Xia, M. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.237453 · Cited by 121
Bai, Y., Soda, Y., Izawa, K., Tanabe, T., Kang, X., Tojo, A., Hoshino, H., Miyoshi, H., Asano, S., & Tani, K. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302026 · Cited by 68
Cited by
Spermidine in health and disease
Madeo, F., Eisenberg, T., Pietrocola, F., & Kroemer, G. (2018) · Science · doi:10.1126/science.aan2788 · Cited by 1,154
Lysine Acetylation Goes Global: From Epigenetics to Metabolism and Therapeutics
Ali, I., Conrad, R. J., Verdin, E., & Ott, M. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00181 · Cited by 366
Self-citationReducing acetylated tau is neuroprotective in brain injury
Shin, M.-K., Vázquez-Rosa, E., Koh, Y., Dhar, M., Chaubey, K., Cintrón-Pérez, C. J., Barker, S., Miller, E., Franke, K., Noterman, M. F., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.032 · Cited by 226
Lifespan-increasing drug nordihydroguaiaretic acid inhibits p300 and activates autophagy
Tezil, T., Chamoli, M., Ng, C.-P., Simon, R. P., Butler, V. J., Jung, M., Andersen, J., Kao, A. W., & Verdin, E. (2019) · npj Aging and Mechanisms of Disease · doi:10.1038/s41514-019-0037-7 · Cited by 40
Self-citationAutophagy-mediated metabolic effects of aspirin
Castoldi, F., Humeau, J., Martins, I., Lachkar, S., Loew, D., Dingli, F., Durand, S., Enot, D., Bossut, N., Chery, A., et al. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-00365-0 · Cited by 27
Metadata
- Authors
- Shirakawa, K., Wang, L., Man, N., Maksimoska, J., Sorum, A. W., Lim, H. W., Lee, I. S., Shimazu, T., Newman, J. C., Schröder, S., Ott, M., Marmorstein, R., Meier, J., Nimer, S., & Verdin, E.
- Venue
- eLife
- Publisher
- eLife Sciences Publications, Ltd
- Published
- 2016-05-31
- Volume
- 5
- ISSN
- 2050-084X (ISSN-L)
- OpenAlex
- W2415329378
- Cited by
- 71
- References
- 9
- FWCI
- 4.36
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Salicylate, diflunisal and their metabolites inhibit CBP/p300 and exhibit anticancer activity. https://app.cochat.ai/papers/10.7554/elife.11156
- The paper
- Shirakawa, K., Wang, L., Man, N., Maksimoska, J., Sorum, A. W., Lim, H. W., Lee, I. S., Shimazu, T., Newman, J. C., Schröder, S., Ott, M., Marmorstein, R., Meier, J., Nimer, S., & Verdin, E. (2016). Salicylate, diflunisal and their metabolites inhibit CBP/p300 and exhibit anticancer activity. eLife. https://doi.org/10.7554/elife.11156
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.